COVID-19, page-12

This today.....

The Company's entry into a binding supply agreement for the supply of Atomo devices to be used for a blood-based lateral flow rapid test
to detect Covid-19 virus with NG Biotech, Inc (NG Biotech), an existing OEM customer of the
Company in France. The initial order under the agreement is for the supply of 397,200 devices, which
represents the Company’s available inventory and next production batch available for sale in early
April. The agreement provides NG Biotech with the right to issue purchase orders for up to a total of
2.465 million devices (including the initial 397,200 devices) in the 2020 calendar year, which may
increase or decrease subject to Atomo's production capacity. NG Biotech commits to order at least
70% of the monthly quantities agreed with Atomo and should NG Biotech fail to meet its minimum
order commitment, then Atomo shall be released from its commitment to reserve capacity of 2.465
million devices for NG Biotech. The Company and NG Biotech intend to enter into a further binding
purchase agreement for the ongoing supply of Atomo products beyond 2020.

Looking good.